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Models of human disease have long been used to understand the basic pathophysiology of disease and to
facilitate the discovery of new therapeutics. However, as long as models have been used there have been debates
about the utility of these models and their ability to mimic clinical disease at the phenotypic level. The
application of genetic studies to both humans and model systems allows for a new paradigm, whereby a novel
comparative genomics strategy combined with phenotypic correlates can be used to bridge between clinical
relevance and model utility. This study presents a comparative genomic map for “candidate hyper-
tension loci in humans” based on translating QTLs between rat and human, predicting 26 chromosomal regions
in the human genome that are very likely to harbor hypertension genes. The predictive power appears robust,
as several of these regions have also been implicated in mouse, suggesting that these regions represent primary
targets for the development of SNPs for linkage disequilibrium testing in humans and/or provide a means to
select specific models for additional functional studies and the development of new therapeutics.
Genetic studies of multifactorial disorders such as hy-
pertension in human populations remain challenging
because of multiplicity of genes underlying complex
phenotypes, the modest nature of gene effects, and the
inevitable heterogeneity of the patient population. Be-
cause of the limited success in identifying genes in-
volved in complex traits using linkage studies, map-
based association studies and linkage disequilibrium
tests have gained momentum as novel approaches,
supported by the rapid development of “third genera-
tion” markers based on single-nucleotide polymor-
phisms (SNPs) (Wang et al. 1998; Marshal 1999). These
studies require a very high density of genetic markers
and sophisticated statistical tools to analyze large
marker sets (Lander 1996; Collins et al. 1997; Kruglyak
1997). Once a region is established to harbor a major
disease gene, there is potential for advanced “finished”
sequencing of these regions (Collins et al. 1998). The
huge human and economic cost of hypertension war-
rants an accelerated discovery pathway for SNP devel-
opment and advance finished sequencing of regions
containing the disease genes. However, little is known
about the genetic basis of human hypertension or any
other multifactorial disorder (e.g., diabetes, myocardial
infarction, psychiatric disease), limiting these novel
strategies until a high-density SNP map is available.
Studies on the genetic basis of hypertension have
discovered multiple quantitative trait loci (QTLs) pre-
dominantly in rat models (Hamet et al. 1998) and en-
couraged studies in human populations using the can-
didate gene approach (Jeunemaitre et al. 1992a,b;
Casari et al. 1995). However, with the exception of rare
monogenic forms (Shimkets et al. 1994; Simon et al.
1996a,b), limited progress has been made in the iden-
tification of underlying genetic factors of essential hy-
pertension and case/control studies using the candi-
date gene approach have yielded conflicting results
(Jeunemaitre et al 1992a,b; Harrap et al. 1993; Iwai et
al. 1994; Casari et al. 1995; Kato et al. 1998; Brand et al.
1998; Niu et al. 1998). A recent study in the mouse has
also identified QTLs within the mouse genome con-
tributing to hypertension (Wright et al. 1999). There-
fore, we developed a novel comparative genomics
strategy for using QTLs from various rat models for
genetic hypertension to prioritize regions of the hu-
man genome for focused SNP discovery and linkage
disequilibrium testing. A sufficient number of high-
quality genetic studies conducted in human and
mouse provided a means to validate our strategy. In
addition to prioritized regions for high-density geno-
typing in humans using SNPs, the data presented here
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also provide investigators with valuable phenotype
and mapping information on blood pressure pheno-
types that may be beneficial for positional cloning ef-
forts and drug discovery, for example, using congenic
animals. Here, we report a total of 67 QTLs for 39 blood
pressure traits in the progenies of seven F2 rat inter-
crosses for genetic hypertension on the basis of which
26 homologous regions are prioritized target regions
Table 1. Hypertension-Related QTLs Identified in the Progenies of Genetically Hypertensive Rats and Syntenic
Chromosomal Regions in Human Genome Based on Cytogenetics
Data shown represent the 99% C.I. for each QTL trait. The total genetic distance covered by QTLs in the rat was 567.6 cM based on
a drop of 1.6 lod units from the peak. For detailed phenotype description and abbreviation please see Table 3. QTLs 10, 11, 23, 27,
55, 61, 62, 63, 64, 65, and 66 were mapped nonparametrically using the ‘np scan’ option available in MAPMAKER/QTL (v.1.9).
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for human genetic studies. Importantly, when validat-
ing our strategy by comparing our results with those
from recent genome-wide scans in human populations
(Julier et al. 1997; Mansfield et al. 1997; Krushkal et al.
1998), five out of the six known QTLs for human hy-
pertension were correctly predicted based on our stud-
ies using rat models. Additionally, seven QTLs for
blood pressure identified recently in the mouse
(Wright et al. 1999) fall within four intervals identified
in our rat studies, one of which has been confirmed in
humans (Krushkal et al. 1999). Therefore, the predicted
human regions represent genetically validated targets
for linkage disequilibrium testing using SNPs.
RESULTS
Using the total genome scan approach, we identified a
total of 67 QTLs for a total of 39 blood pressure-related
traits (see Methods for details) in seven F2 progenies
(Table 1) derived from different genetically hyperten-
sive rat strains. These 67 QTLs were
integrated on an integrated map
and clustered in 15 independent ge-
nomic regions. An example for con-
struction of a cluster is shown in
Figure 1. Table 1 shows the location
of the QTLs identified, including
the genetic markers flanking the
combined 99% confidence interval
(C.I.), genetic distance covered, and
lod scores for the given trait in the
respective rat intercross, in total,
~ 500 cM, ~ 30% of the rat genome.
Comparative maps were con-
structed based on conserved ge-
nomic regions and evolutionary
breakpoints between rat, mouse,
and human genomes (Fig. 2) using
homologous genes as anchors.
Based on these comparative maps,
the 67 QTLs identified in the rat were translated to 26
chromosomal segments that are located on 16 auto-
somes in the human genome (Fig. 3; Table 2). Of these
segments, 20 come from 8 distinct QTL clusters (re-
gions of overlapping QTLs) identified on rat chromo-
somes 1, 2, 3, 4, 8, 13, and 18 (Table 1) and are desig-
nated as first priority regions covering ~ 22.5% of the
human autosomal genome. These clusters represent ar-
eas where multiple blood pressure-related traits were
linked in multiple crosses and, therefore, are likely to
be essential regions. Five regions predicted based on
our rat studies (1q, 2p13, 5q31, 15q22, and 17q) were
recently identified in genome-wide scans for human
hypertension (Julier et al. 1997; Mansfield et al 1997;
Krushkal et al. 1998) (Fig. 3, flagged with a star). Table
2 provides the 26 predicted chromosomal segments of
the human genome based on cytogenetics as well as a
list of the 412 genetic markers currently available based
on GeneMap98 at the National Center for Biotechnol-
ogy Information (NCBI). This table also lists some of
the obvious candidate genes within each interval.
The 26 regions in the human genome represent
~ 30% of the genome, suggesting that the overlap be-
tween the rat and human data could be a chance oc-
currence. Estimates on the bin size of QTL regions in
rat and human genomes, respectively, showed that our
predictions of target regions in the human genome
were not due to chance (z-test, P < 0.001; see Methods
for details). Furthermore, five out of six regions have
been identified in genome scans in humans, with two
of the predicted regions (5q and 17q) confirmed in two
independent studies. Moreover, recent studies in the
mouse have identified several QTLs that contribute to
high blood pressure in this model. The mouse QTLs are
syntenic with the QTLs on rat chromosomes 2, 3, 8,
and 18 and on predicted regions on human chromo-
Figure 1 Demonstration of QTL clustering. The dark-shaded area of the QTL profile
represents the 99% C.I. of each QTL. The dark vertical lines indicate the boundary of the
QTL cluster, which is defined by the nearest two markers flanking the combined 99% C.I,
in this example D1Mgh9 and D1Mgh5.
Figure 2 Flow chart showing the algorithm for constructing
framework comparative maps between rat, mouse, and human
genomes based on publicly available databases.
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somes 2q14–q23, 3p11–3p21.3, 3q21–q26.6, 4q25–
q28, 5p14–q12, and 18q21–q23, further suggesting
conserved regions contributing to blood pressure regu-
lation (Fig. 3).
DISCUSSION
The recent improvement of analytical techniques in
molecular genetics has provided powerful tools to
identify the genes involved in heritable diseases. How-
ever, polygenic disorders in humans remain challeng-
ing. Power estimates suggest that identification of
genes responsible for common polygenic disorders will
most likely come from association studies (Risch and
Merikangas 1996). Unfortunately, association studies
require specific candidate genes or closely spaced
markers (at an average spacing of at most 150 kb) to be
tested. Given that the third generation map of the hu-
man genome is not immediately available, there is a
need to select candidate regions for early SNP develop-
ment. Our strategy is to use animal models. Prior to
this publication, investigators have used QTLs in the
rat to select candidate genes for testing in human
populations. For example, we and others have reported
Figure 3 Human chromosomal regions implicated in hypertension based on rat–human comparative maps for 67 QTLs identified in
seven different progenies from genetically hypertensive rats. Distribution of the 26 predicted genomic regions in the human genome
located on 16 different autosomes based on cytogenetics. Human chromosomes 6, 12, 14, 20, 21, and 22 do not contain positional
candidate loci predicted by the rat studies, and the sex chromosomes were not evaluated in this study. Regions of the genome in which
multiple blood pressure-related phenotypes cluster from more than one cross are designated first priority regions. There are 20 of 26
regions that fall into this category (boxed regions). We predict six “second priority regions” based on QTLs identified in a single rat cross
that may represent either areas of interest for a distinct subtype of hypertension or areas harboring modifier genes for blood pressure
(nonboxed regions). Confidence level for placement of syntenic regions designated by vertical bars: (Red) Highest, (blue) high, (black)
moderate. Numbers: (Black) SHR 2 BN, (purple) SS/MCW 2 BN, (blue) SHR 2 WKY, (red) SHR 2 DRY, (dark green) ACI 2 FHH, (light
green) GH 2 BN, (magenta) LH 2 LN. Mouse syntenic QTLs are represented by the vertical bars to the left of the human idiograms. (Star)
Genomic region reported with significant or suggestive linkage in genome scans for hypertension in humans.
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Table 2. Predicted Chromosomal Segments in the Human Genome Based on Synteny to Blood Pressure QTLs in the Rat
Genetic markers and candidate genes provided represent markers, as mapped and listed in GeneMap98. Homologous regions are
listed in relation to the respective genetic location in the rat, and putative candidate genes were chosen based on MIM-Maps and
verified for map position in the syntenic region in mouse/rat using the MGD. Of 67 QTLs, 64 were converted to discrete homologous
regions in the human genome; 3 QTLs (QTLs 43, 44, and 50) could not be converted because of incomplete coverage of the rat
genetic map or lack of homologous genes being mapped between rat, mouse, and human.
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that a QTL identified in the rat harboring the angio-
tensin converting enzyme (ACE) gene was linked to
high blood pressure (Hilbert et al. 1991; Jacob et al.
1991). Quickly following these publications, Jeune-
maitre et al. (1992a) reported that ACE was not linked
to hypertension in humans. Nonetheless, ACE was
tested in many populations with the majority of the
studies concluding that the human ACE gene was not
linked to hypertension (Staessen et al. 1997). However,
other genes in the vicinity of ACE could not be ruled
out. Two recent publications reporting that QTLs in
the region of ACE were linked to high blood pressure in
humans (Julier et al. 1997; Mansfield et al. 1997) sug-
gested that QTLs identified in the rat may be predic-
tive. Therefore, we constructed a comparative genomic
map for “candidate hypertension loci in humans”
based on translating QTLs between rat and human,
and vice versa. As this is a novel strategy, it was fun-
damental to validate the approach. For validation, we
compared our predictions with results from the litera-
ture (Julier et al. 1997; Mansfield et al. 1997), the Fam-
ily Blood Pressure Program (Krushkal et al. 1998, 1999) as
well as results from studies in the mouse (Wright et al.
1999). Strikingly, there was tremendous overlap between
the QTLs identified in the rat, mouse, and human. The
identification of a genomic interval where blood pressure
QTLs were identified across human (2q14–q23), mouse
(chromosome 2), and rat (chromosome 3) genomes fur-
ther supports the power of comparative mapping and
validates the use of this strategy. As more studies are un-
derway, for example, in the mouse, we expect additional
QTLs to be identified that are likely to coincide with
blood pressure loci in the syntenic regions of the rat.
We studied seven different rat crosses that repre-
sent five of the nine inbred strains of genetically hy-
pertensive rats (Stoll and Jacob 1999) and identified
67 QTLs for 39 blood pressure traits. Many of the
loci presented in Table 1 have also been reported by
other investigators (Hamet et al. 1998), providing ad-
ditional evidence that these loci play a major role in
high blood pressure in the rat. Interestingly, none of
the QTLs in the rat were found in all seven crosses,
illustrating the degree of locus heterogeneity (different
genes) that exists even in a simplified model. We have
also found that age and method of blood pressure mea-
surement affect QTL mapping (data not shown). Be-
cause the different genetically hypertensive rats dis-
play different etiologies of hypertension, we reasoned
that the integration of the results from all crosses
would collectively mimic the heterogeneous clinical
picture of hypertension and the homologous human
region candidates for investigation. The data presented
here could be used in human association studies. Such
a strategy has been used to investigate sequence varia-
tion across two candidate genes, ACE (Keavney et al.
1998; Rieder et al. 1999) and lipoprotein lipase gene
(Nickerson et al. 1998), illustrating the power of using
SNPs and haplotype structure (even within a single
gene) in the localization and identification of high-risk
susceptibility mutations for complex diseases. As a
starting point for developing SNPs in the regions im-
plicated, we provide a list of the 412 genetic markers
currently available for the 26 regions of the human ge-
nome in Table 2. These markers can be used to determine
ESTs that are harbored within the interval, which in turn
can be used to develop SNPs in coding regions. Further-
more, the limited number of “first priority regions” (rep-
resenting 22.5% of the autosomal genome) implicated in
blood pressure regulation could be rapidly developed and
tested in the existing collections of patient populations
for essential hypertension. As more genetic studies are
completed in humans, we predict that the number of
syntenic regions for the blood pressure QTLs will also
increase, many in the regions predicted here.
Although the predictive power of comparative
mapping can be used to prioritize regions to develop
large numbers of SNPs, the most likely important as-
pect of these data is that they provide investigators
with a means to select a model system that shares phe-
notypic and genomic content with a clinical popula-
tion. In this regard, developing specific congenics (de-
signer congenics) that share phenotypic and genotypic
characteristics would yield a powerful platform for
functional studies, especially with respect to the physi-
ology and pharmacology of the cardiovascular system.
Furthermore, well-defined genetic models open a wide
range of possibilities for the identification of targets
and the development of new therapeutics. Finally, the
cloning and functional characterization of susceptibil-
ity genes for multifactorial diseases will most probably
require animal model systems. Here, we illustrated that
as comparative maps improve and more biological
traits are linked to the genome, it will become increas-
ingly easier to integrate the power of functional studies
in animal models into a greater understanding of human
diseases and, hopefully, improved therapeutic outcomes.
METHODS
Linkage Analysis of Hypertension-Related Traits
in Various Genetically Hypertensive Rat Intercrosses
This study used five different hypertensive rat strains: the spon-
taneously hypertensive rat (SHR); the Dahl salt-sensitive rat re-
derived at the Medical College of Wisconsin (SS/MCW); the
Lyon hypertensive (LH) rat; the fawn hooded hypertensive rat
developed at Erasmus University (FHH/EUR) and the genetically
hypertensive rat (GH); and four different normotensive strains,
the Brown–Norway (BN), the Lyon normotensive (LN) rat, Au-
gust, Copenhagen, and Irish (ACI), and Donryu (DRY). Seven
sets of F2 intercross progeny from mating genetically hyperten-
sive and normotensive inbred strains (SHR 2 WKY, SHR 2 BN,
SS 2 BN, LH 2 LN, FHH/EUR 2 ACI, GH 2 BN, and
SHR 2 DRY) totaling 1687 animals and 39 blood pressure-
related phenotypes were studied. The protocols for each study
Target Regions for Human Hypertension
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and the methods for estimating blood pressure varied between
the seven studies; therefore, each estimate of blood pressure is
treated as an independent estimate to avoid biasing the data set.
The details of the specific experimental protocols used for some
of the studies were described previously (Harris et al. 1995;
Schork et al. 1995; Brown et al. 1996; Innes et al. 1998) and are
summarized in Table 3. For linkage analysis, genomic DNA was
extracted from liver and spleen using standard methods (Jacob
et al. 1995). Genome-wide scans for all autosomes were per-
formed independently in each cross using between 180 and 250
polymorphic simple sequence length polymorphism (SSLP)
markers with an average spacing of 10 cM as described previ-
ously (Schork et al. 1995; Brown et al. 1996; Innes et al. 1998).
Phenotype distributions were tested for normality using the Kol-
mogorov-Smirnov (KS) test (Fisher and van Belle 1996) prior to
parametric and/or nonparametric linkage analysis using the
MAPMAKER/QTL computer package (v. 1.9) (Lander et al.
1987). Thresholds for the lod scores were established for our
cross structure in accordance with Lander and Kruglyak (1995),
where a lod score >2.8 was suggestive and a lod score >4.3 was
significant for an F2 intercross. Eighty-two percent (55 out of 67)
of the rat QTLs were >2.8. In addition, 12 QTLs with an lod score
of >2.5 were included under the premise that they were located
in a genomic region that contained at least one more QTL that
reached a minimal lod score of 2.8. The 99% C.I. for each QTL
in a given cross was determined by calculating the genetic dis-
tance based on the drop of 1.6 lod units from the peak. The use
of the 1.6 lod unit drop to define the C.I., rather than the tra-
ditional lod drop of 1, results in an expansion of the interval by
~ 25%. However, we believe this more conservative approach is
critical to minimize the number of type II errors (missed link-
ages), when translating between species in a predictive way.
Table 3. Phenotype Designation Key for Mapped QTLs in Progenies from Hypertensive Rat Strains
Rat cross Phenotype description
Max DBP SHR 2 SKY maximal diastolic blood pressure
Max SBP SHR 2 WKY maximal systolic blood pressure
Max MAP SHR 2 WKY maximal mean arterial blood pressure
DBP SHR 2 WKY diastolic blood pressure (baseline)
SBP SHR 2 WKY systolic blood pressure (baseline)
MAP SHR 2 WKY mean arterial blood pressure (baseline)
MAP SHR 2 DRY mean arterial blood pressure
SBP FHH 2 ACI systolic blood pressure
PP LH 2 LN pulse pressure
Hs basal MAP SS 2 BN mean arterial blood pressure, arterial catheter implanted, 4 weeks high salt diet (8%)
mean of measurements on 3 consecutive days, basal state—lights on and rat asleep
Day2 MAP SS 2 BN mean arterial blood pressure, 4 weeks high salt diet (8%), day 2 measurement
Baseline BP SHR 2 BN baseline blood pressure average of 30 min on regular diet
SBP LH 2 LN systolic blood pressure
DBP LH 2 LN diastolic blood pressure
MAP LH 2 LN mean arterial blood pressure
MAPS SHR 2 BN mean arterial blood pressure average of 30 min after 14 days high salt diet on 1% NaCl
SBPS SHR 2 BN systolic blood pressure average of 30 min after 14 days high salt diet on 1% NaCl
DBPS SHR 2 BN diastolic blood pressure average of 30 min after 14 days high salt diet on 1% NaCl
Salt PP SHR 2 BN pulse pressure average of 30 min after 14 days high salt diet on 1% NaCl
DSBP SHR 2 WKY systolic blood pressure, change from baseline after ‘startle’
Tail BP GH 2 BN blood pressure measured by sphygomanometer
ia BP GH 2 BN intra-arterial blood pressure
D_wake_m_day2a
m_SBP
SS 2 BN systolic blood pressure, high salt diet, p.m. active state value minus a.m. basal state
Delta_hs_m_ls_MAP SS 2 BN mean arterial pressure, high salt minus low salt, basal state—lights on and rat asleep
DMAP SHR 2 WKY mean arterial pressure, change from baseline after startle
DPP% SHR 2 WKY pulse pressure, percent change from baseline after startle
DSBP% SHR 2 WKY systolic blood pressure, percent change from baseline after startle
DMAP% SHR 2 WKY mean arterial pressure, percent change from baseline after startle
DMAP SHR 2 BN delta mean arterial pressure after 14 days (1% NaCl) minus mean arterial pressure on low salt
DMAP% SHR 2 BN delta mean arterial pressure after 14 days (1% NaCl) minus mean arterial pressure on
low salt expressed as percentage
DSBP% SHR 2 BN delta systolic blood pressure after 14 days (1% NaCl) minus systolic blood pressure on
low salt expressed as percentage
DSBP SHR 2 BN delta systolic blood pressure after 14 days (1% NaCl) minus systolic blood pressure on
low salt
Delta_wake_m_day2a
m_MAP
SS 2 BN mean arterial blood pressure, high salt diet, p.m. active state value minus a.m. basal state
Delta_hs_m_ls_SBP SS 2 BN systolic blood pressure, high salt minus low salt, basal state—lights on and rat asleep
Hs basal SBP SS 2 BN systolic blood pressure, arterial catheter implanted, 4 weeks high salt diet (8%) mean of
measurements on three consecutive days, basal state—lights on and rat asleep
Hs active MAP SS 2 BN mean arterial pressure, arterial catheter implanted, high salt diet, active state—lights off
and rat awake
Day1 MAP SS 2 BN mean arterial blood pressure, 4 weeks high salt diet (8%), day 2 measurement
Captopril SHR 2 BN mean arterial blood pressure after administration of Captopril
Hexamethonium SHR 2 BN mean arterial blood pressure after administration of Captopril and Hexamethonium
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Generation of QTL Clusters Among the Various Crosses
Blood pressure-related QTLs (99% C.I.) with a lod score >2.8
lod units identified in the rat progenies were integrated into a
map that was constructed based on genetic information of all
crosses used. Clusters of QTLs in the same genomic region
were defined as the genomic region in which two or more
pressure-related QTLs overlapped within their 99% confi-
dence intervals. The boundary for each “QTL cluster” was
defined by the two nearest markers flanking the “combined
99% C.I.” as opposed to the average 99% C.I. (Fig. 1).
Construction of Comparative Maps Between Rat
and Human
Map construction was initiated by building framework maps,
which were constructed by identifying genes in evolutionarily
conserved genomic regions among mammalian species (hu-
man, mouse, and rat) that were mapped in rat and mouse and
were listed in at least one database containing rat genome
data (http://ratmap.gen.gu.se; http://www.well.ox.ac.uk).
Conserved regions and evolutionary breakpoints between rat
and mouse genomes were identified using the Mouse Genome
Database (MGD) with the mapped genes serving as anchoring
points within the published genetic maps for both species.
The order of genes was determined in the mouse using linkage
groups available at MGD (http://www.informatics.jax.org)
identifying conserved regions and evolutionary breakpoints
between rat and mouse genomes. This information was used to
define regions of conserved gene order and evolutionary break-
points with the human genome, using mapping information of
homologous genes in the human genome available in MGD,
The Genome Database (http://gdbwww.gdb.org), and the Uni-
Gene set at the NCBI (http://www.ncbi.nlm.nih.gov). (Fig. 2).
Integration of QTL Clusters onto the Homologous
Regions of the Human Genome
Based on the comparative maps between rat, mouse, and hu-
man genomes, rat QTL clusters were integrated onto the hu-
man genome at three confidence levels. The criteria for place-
ment were as follows: (1) highest confidence level: Both mark-
ers flanking the 99% C.I. were gene based and define a region
of conserved gene order between rat and human and several
additional genes within the interval provide additional con-
fidence. (2) High confidence level: one flanking marker is
gene based; the other flanking markers is anonymous but in
close proximity (~ 5 cM) of a gene mapped in both species.
Several additional markers or genes within the interval agree
with the defined conserved region. (3) Moderate confidence
level: Flanking markers are anonymous but in the vicinity of
mapped genes ( ~ 5 cM). Additional markers within the inter-
val help to include or exclude genomic regions. The cytoge-
netic location and, when possible, the respective human ge-
netic markers defining the boundaries for the predicted ge-
nomic regions were established based on mapped genes in the
Human GeneMap98 at NCBI (http://www.ncbi.nlm.nih.gov/
genemap98) (Deloukas et al. 1998).
Likelihood to Identify Predicted QTLs in Human Studies
To determine accuracy of QTL prediction across species, vari-
ous statistical tests were performed to assay for likelihoods
that the observed correct predictions of five QTLs identified in
human studies were not a chance occurrence. For this, z-tests
and x2 tests were performed based on the following assump-
tions: The genomic distance covered by rat QTLs and by pre-
dicted regions was ~ 30% of the complete autosomal genome.
If this hypothesis was correct, we would have expected that
two of the six (one-third) confirmed human regions would
map to the predicted region by chance. Yet five of six (five-
sixths) did. In a more stringent test, the genomic regions were
binned based on the observed average genomic distance cov-
ered by a QTL (30 cM in the rat) and the average size of the
homologous region in the human genome (50 cM). In the rat,
15 out of 50 bins showed a linkage with suggestive/significant
lod scores for blood pressure QTLs, whereas in the human ge-
nome, 26 out of 60 bins were predicted. A z-test showed a sig-
nificant difference between the frequencies with a P < 0.001,
confirming that our observation was not a chance occurrence.
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